Glenmark Pharmaceuticals' Q2 FY 2025-26 Quarterly Results

Result Summary

• Glenmark Pharmaceuticals Ltd reported a 89.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 79.9%.
• Its expenses for the quarter were up by 35.6% QoQ and 29.8% YoY.
• The net profit increased 1199.6% QoQ and increased 72.2% YoY.
• The earnings per share (EPS) of Glenmark Pharmaceuticals Ltd stood at 21.62 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Glenmark Pharmaceuticals Ltd is a global pharmaceutical company engaged in the development, manufacturing, and marketing of branded and generic formulations. It operates across various therapeutic areas, including dermatology, respiratory, and oncology, among others. As of the latest data, Glenmark has a strong presence in both emerging and developed markets, with a focus on innovation and research in specialty and generics pharmaceuticals. The company is known for its robust pipeline of drug candidates and has been investing in R&D to enhance its offerings. Specific recent major developments are not available in the provided data.

Revenue

In Q2FY26, Glenmark Pharmaceuticals Ltd reported a total income of ₹6,247.50 crores, a significant increase from ₹3,290.88 crores in Q1FY26 and ₹3,473.21 crores in Q2FY25. This reflects a quarter-over-quarter (QoQ) growth of 89.8% and a year-over-year (YoY) increase of 79.9%. The substantial rise in revenue indicates a robust quarter for the company, showcasing a significant improvement in its financial performance compared to previous periods. The increase in total income may be attributed to a variety of factors, including potential growth in product demand and expansion in market reach, although specific drivers are not detailed in the data provided.

Profitability

The company's profitability metrics for Q2FY26 show remarkable growth. Profit Before Tax (PBT) reached ₹967.40 crores, up from ₹95.58 crores in Q1FY26 and ₹472.57 crores in Q2FY25, marking a QoQ rise of 912.1% and a YoY increase of 104.7%. After accounting for taxes amounting to ₹356.97 crores, Glenmark's Profit After Tax (PAT) was ₹610.43 crores, compared to ₹46.97 crores in Q1FY26 and ₹354.48 crores in Q2FY25. This represents a QoQ growth of 1199.6% and a YoY increase of 72.2%. The Earnings Per Share (EPS) followed a similar trajectory, with a value of ₹21.62 in Q2FY26, demonstrating a QoQ growth of 1202.4% from ₹1.66 in Q1FY26, and a YoY increase of 72.3% from ₹12.55 in Q2FY25. These figures indicate a significant upswing in profitability for the quarter.

Operating Metrics

Glenmark Pharmaceuticals Ltd's total expenses for Q2FY26 were ₹3,894.98 crores, up from ₹2,872.08 crores in Q1FY26 and ₹3,000.64 crores in Q2FY25. This represents a 35.6% QoQ increase and a 29.8% YoY increase. Despite the rise in expenses, the company's growth in total income and profitability suggests a positive operational performance for the quarter. The data does not provide specific details on cost management strategies or changes in operational efficiencies. However, the substantial growth in revenue and profits, alongside increased expenses, is a notable aspect of the company's financial performance for this period. The report does not include specific financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio, as these require additional data not provided.